Expert Interview
Looking at the Recent FDA Approval for GSK’s Blenrep (belantamab mafodotin-blmf) Combination Therapy for Relapsed/Refractory Multiple Myeloma
Ticker(s): GSKInstitution: Mayo Clinic
- Professor of Medicine in the Division of Hematology/Oncology at the Mayo Clinic Florida
- Manages 50 patients with Waldenström's macroglobulinemia and can speak to the data available for iopofosine and the CLOVER-WaM study.
- Clinical focus includes the treatment of plasma cell disorders, multiple myeloma (MM), Waldenström's macroglobulinemia, and chronic lymphocytic leukemia (CLL).
Do you anticipate broader adoption of Blenrep in community oncology settings, given its accessibility versus other BCMA-directed therapies (e.g., CAR-T, bispecifics)?
Added By: sara_adminGiven Blenrep’s known ocular toxicity profile, how do you view the updated REMS program? Does the streamlined approach meaningfully reduce barriers to use in clinical practice?
Added By: sara_adminWhere do you see Blenrep + bortezomib/dexamethasone fitting in the current treatment sequence for patients who have received at least two prior lines of therapy?
Added By: sara_adminAre there specific patient types, based on prior therapies, cytogenetics, or comorbidities, who you believe may particularly benefit from the Blenrep combination?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
